Validation of the UVA Simulation Replay Methodology Using Clinical Data: Reproducing a Randomized Clinical Trial
Authors' conclusion
Clinical trial data confirm the prior in silico validation of the UVA replay method in predicting the glycemic impact of modified insulin treatments.
Study context
- Population
- People with T1D in a randomized crossover trial comparing hybrid closed loop (HCL) and fully closed loop (FCL) automated insulin delivery (AID)64 subject/modality pairs
- Comparison
- Simulated vs observed glycaemic outcomes of HCL and FCL AID modalities
- Outcome
- Equivalence of simulated vs observed TIR, TBR, TAR, HBGI and LBGI, with equivalence margins corresponding to clinical significance
Methodological detailsreplay methodology, equivalence tests, data from randomized crossover clinical trial
- Replay methodology
- Equivalence tests
- Data from randomized crossover clinical trial
Performance
As reported in the abstract
Equivalence of simulated vs observed glycaemic outcomes
- TIR, TAR, LBGI and HBGI showed statistical and clinical equivalence between original and simulated data
- TBR failed the equivalence test
Further findings
TIR, HCL mode · equivalence test
(CI −3.96 to 2.79) · P = 0.0170
TIR, FCL mode · equivalence test
(CI −2.54 to 4.20) · P = 0.0222
Original publication
Validation of the UVA Simulation Replay Methodology Using Clinical Data: Reproducing a Randomized Clinical Trial. Diabetes Technol Ther. Published 30 April 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →